Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification. (2023)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1007/s00401-023-02566-0
PubMed Identifier: 37014508
Publication URI: http://europepmc.org/abstract/MED/37014508
Type: Journal Article/Review
Volume: 145
Parent Publication: Acta neuropathologica
Issue: 5
ISSN: 0001-6322